ClinicalTrials.gg
Not yet recruitingNCT07623187EVICTION 3Updated Sep 10, 2026

A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy

A Phase 2/3 interventional study of IPN60340 + azacitidine + venetoclax and Placebo + azacitidine + venetoclax in Acute Myeloid Leukaemia (AML) and Acute Myeloid Leukaemia, sponsored by Ipsen. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Ipsen · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to find out how well the study drug IPN60340 works to treat participants with acute myeloid leukemia. Acute myeloid leukemia is a rare blood cancer that grows quickly. This study's main aim is to compare the percentage of participants who reach complete remission within the first 6 months of treatment between the 2 study arms (study drug and standard medicines compared to placebo and standard medicines).

In this study all participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. Venetoclax will be given as a tablet by mouth once each day in 28-day cycles. Azacitidine will be given by injection under the skin (subcutaneously) or through the veins (intravenously) daily for the first 7 days of each 28-day cycle. IPN60340 or placebo (depending on which arm of the study the participant is assigned to) will be given through the veins (intravenously) on day 1 of each 28-day cycle.

There will be 4 periods in this study:

  • A screening period (up to 28 days) to assess whether the participant can take part requiring at least 1 visit to the study center.
  • A treatment period where all eligible participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. The study requires 8 visits for the first month followed by 1 visit every month until unacceptable toxicity, disease progression, the start of new cancer treatment, or study closure, whichever is first.
  • A safety follow-up period (at 28 days (±3 days) after the last dose of study medicine) to assess safety after participants have finished treatment.
  • A long-term follow-up period where participants' health will be monitored using a telephone call or clinic visit every 12 weeks until the end of study.

Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), bone marrow aspirates (sampling of the liquid part of the bone marrow). Some participants will also undergo pregnancy testing. Participants in the Phase 3 portion of the study will also be asked to fill in questionnaires.

The time each participant will be in this study will vary based on how well the medicine works to treat the participant's AML. Azacitidine and venetoclax plus either IPN60340 or placebo will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.

02

Conditions studied

  • Acute Myeloid Leukaemia (AML)
  • Acute Myeloid Leukaemia
03

In context

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

This study's planned enrollment of 540 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 years of age or older, at the time of signing the .
  2. Have newly diagnosed AML, as per WHO 2022 criteria.
  3. (ECOG) performance status of 1 to 2 for participants ≥75 years of age, or 1 to 3 for participants \<75 years of age
  4. Participants must be considered ineligible for intensive chemotherapy, due to age or comorbidities,
  5. Adequate organ function as indicated in the protocol
  6. use by participant or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
  7. Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Current diagnosis of:

    I. Acute promyelocytic leukemia (APL) II. Active or uncontrolled central nervous system (CNS) leukemia III. Any γ9δ2TC neoplasm

  2. History of myeloproliferative neoplasms (MPN) including primary myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia, or MDS/MPN as per WHO 2022 or treatment-related AML
  3. History of other within the last 2 years.
  4. Rapidly progressing disease in the opinion of the clinical investigator which may preclude treatment in this study.
  5. History of or uncontrolled cardiac disorders, within 6 months prior to Cycle 1 Day 1 (C1D1)
  6. White blood cell (WBC) count >25 × 10\^9/L . Cytoreduction can be used before C1D1 and beyond as needed to keep WBC \< 25 × 10\^9.
  7. Participants with severe hepatic impairment, e.g., C, are excluded.
  8. Major surgery within 4 weeks prior to C1D1 or planned during the foreseeable duration of the study.
  9. Any gastrointestinal disorder or malabsorption syndrome that may impair absorption of venetoclax
  10. Uncontrolled or severe bacterial, fungal, viral, and/or parasitic infections treated with therapeutic oral or intravenous anti-infective agents. Prophylactic antimicrobials are allowed.
  11. Uncontrolled (HIV) disease will be excluded. Participants on anti-retroviral therapy should be included as long as their disease is under control, taking precautions to modify their highly active antiretroviral therapy (HAART) regimen to minimize drug interactions.
  12. Presence of surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to randomization.

    NOTE: Participants with known positive HBsAb may be randomized provided they are hepatitis B-vaccinated and have negative HBsAg and HBcAb.

  13. Positive antibody test result at screening or within 3 months of randomization unless HCV-RNA negative test is documented.

    NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled if a confirmatory negative hepatitis C ribonucleic acid (RNA) test is obtained.

  14. Participant has received strong and/or moderate cytochrome P450 (CYP)3A inducers within 7 days prior to the initiation of study treatment.
  15. Participant is unable to swallow capsules or tablets
  16. Prior treatment with hypomethylating agents, chemotherapy, B-cell lymphoma protein (BCL) 2 inhibitors, clinical trial therapy, cellular therapy or allogenic hematopoietic cell transplantation (HCT) for MDS.
  17. Treatment with systemic of >10 mg/day prednisone (or equivalent) or other systemic medications within 5 half-lives prior to C1D1, or anticipated requirement for systemic immunosuppressive medications during the study.
  18. Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator [or medical monitor], contraindicates participation in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    IPN60340 in combination azacitidine plus venetoclax (IAV)

    In phase 2b, approximately 90 participants will be randomized in a 1:1 ratio to IAV. In phase 3, approximately 450 participants will be randomized in a 1:1 ratio to IAV. Regardless of the phase, participants will be randomized prior to dosing. Participants who are enrolled in phase 2b of the study will not be allowed to enroll in phase 3 of the study.

    Biological: IPN60340 + azacitidine + venetoclax

  • Active comparator
    Placebo in combination azacitidine plus venetoclax (PAV)

    In phase 2b, approximately 90 participants will be randomized in a 1:1 ratio to PAV. In phase 3, approximately 450 participants will be randomized in a 1:1 ratio to PAV. Regardless of the phase, participants will be randomized prior to dosing. Participants who are enrolled in phase 2b of the study will not be allowed to enroll in phase 3 of the study.

    Drug: Placebo + azacitidine + venetoclax

Interventions

  • BiologicalIPN60340 + azacitidine + venetoclax

    Drug page: Anti-BTN3A Agonistic Monoclonal Antibody ICT01

    : IPN60340 + azacitidine + venetoclax Participants will receive: * IPN60340 per protocol by intravenous (IV) infusion in each 28-day treatment cycle * azacitidine by subcutaneous (SC) or IV daily for the first week in each 28-day treatment cycle * venetoclax orally daily every day of each 28-day treatment cycle

    Also known as: ICT01

  • DrugPlacebo + azacitidine + venetoclax

    Drug page: Sodium Chloride

    Participants will receive: * Placebo per protocol by intravenous (IV) infusion in each 28-day treatment cycle * azacitidine by subcutaneous (SC) or IV daily for the first week in each 28-day treatment cycle * venetoclax orally daily every day of each 28-day treatment cycle

    Also known as: NaCl

06

What researchers measure

Primary outcomes

  1. (Phase 2b and Phase 3) Percentage of participants with Complete Remission (CR)

    Complete remission (CR) as defined according to ELN 2022 criteria

    Time frame: From randomization to end of Cycle 6 (approximately 6 months)

Secondary outcomes

  1. (Phase 2b) Overall Survival (OS)

    Defined as time from randomization to the date of death from any cause

    Time frame: From randomization until end of study (up to approximately 6 years)

  2. (Phase 2b) Duration of Complete Remission (DoCR)

    Defined as time from achievement of CR to hematological relapse or death from any cause, whichever occurs first

    Time frame: From first documented CR until end of study (up to approximately 6 years)

  3. (Phase 2b) Event-Free Survival (EFS)

    Defined as time from randomization to the date of induction treatment failure (ITF), relapse from complete remission (CR), or death from any cause, whichever occurs first.

    Time frame: From randomization to end of study (up to 6 years)

  4. (Phase 2b) Composite Complete Remission Rate (CRc)

    Composite complete remission (CRc), defined as the composite of complete remission (CR), complete remission with partial hematologic recovery (CRh), and complete remission with incomplete hematologic recovery (CRi), according to ELN 2022 criteria

    Time frame: From randomization to end of Cycle 6 (approximately 6 months)

  5. (Phase 2b) Complete Remission with Minimal Residual Disease Negative (CR MRD-negative)

    Complete remission with minimal residual disease negativity (CR MRD-negative) according to ELN criteria

    Time frame: From randomization to end of cycle 6 (6 months)

  6. (Phase 2b) Composite Complete Remission with MRD Negative (CRc MRD-negative)

    Composite complete remission (CRc), defined as CR, CRh, and CRi, with minimal residual disease (MRD) negativity according to ELN 2022 criteria

    Time frame: From randomization to end of Cycle 6 (approximately 6 months)

  7. (Phase 2b) Transfusion Independence (TI) Conversion Rate

    Transfusion independence (TI) conversion rate, defined as a ≥56-day period without red blood cell (RBC) or platelet transfusion after start of treatment in participants requiring transfusion within 28 days prior to the first dose of study treatment.

    Time frame: From randomization until end of study (up to approximately 6 years)

  8. (Phase 2b) Percentage of participants with Treatment-Related Adverse Events (TEAEs)

    TEAEs with severity grading according to the NCI CTCAE version 6.0, except the severity of CRS and ICANS which will be graded according to the ASTCT Consensus Grading Criteria, from the first administration of study drug up to 28 days after the last dose.

    Time frame: From first administration of study drug up to 28 days after last dose

  9. (Phase 3) Overall Survival (OS)

    Overall survival (OS), defined as the time from randomization to death from any cause

    Time frame: From randomization until end of study (up to approximately 6 years)

  10. (Phase 3) Duration of Complete Remission (DoCR)

    Duration of complete remission (DoCR), defined as the time from achievement of CR to hematological relapse or death from any cause, whichever occurs first

    Time frame: From first documented CR until end of study (up to approximately 6 years)

  11. (Phase 3) Event-Free Survival (EFS)

    Event-free survival (EFS), defined as the time from randomization to induction treatment failure (ITF), relapse from CR, or death from any cause, whichever occurs first

    Time frame: From randomization until end of study (up to approximately 6 years)

  12. (Phase 3) Composite Complete Remission (CRc)

    Composite complete remission (CRc), defined as CR, CRh, and CRi according to ELN 2022 criteria

    Time frame: From randomization to end of Cycle 6 (approximately 6 months)

  13. (Phase 3) Complete Remission with Minimal Residual Disease Negative (CR MRD-negative)

    Complete remission with minimal residual disease negativity (CR MRD-negative) according to ELN criteria

    Time frame: From randomization to end of Cycle 6 (approximately 6 months)

  14. (Phase 3) Composite Complete Remission with MRD Negative (CRc MRD-negative)

    Composite complete remission (CRc), defined as CR, CRh, and CRi, with MRD negativity

    Time frame: From randomization to end of Cycle 6 (approximately 6 months)

  15. (Phase 3) Transfusion Independence (TI) Conversion Rate

    Transfusion independence (TI) conversion rate, defined as a ≥56-day period without red blood cell (RBC) or platelet transfusion after start of treatment in participants requiring transfusion prior to study entry

    Time frame: From randomization until end of study (up to approximately 6 years)

  16. (Phase 3) Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status, fatigue, and physical functioning subscales

    Change from baseline in global health status, fatigue, and physical functioning subscales

    Time frame: From baseline until end of study (up to approximately 6 years)

  17. (Phase 3) Percentage of Participants Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

    Percentage of participants undergoing HSCT in remission following study treatment

    Time frame: From baseline until end of study (up to approximately 6 years)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2031, 54 months later.

Of 31 phase 2/3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 86. This study's planned 54 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
May 31, 2031
CompletionEst.
May 31, 2032
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623187
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
May 31, 2031 (estimated)
Completion
May 31, 2032 (estimated)
Last update
Sep 10, 2026

Study contacts

Ipsen Clinical Study Enquiries
Contact
clinical.trials@ipsen.com
See email

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-BTN3A Agonistic Monoclonal Antibody ICT01

Start the discussion